Skip to content

MIST: Multimodal Survival Prediction with Genomic-Guided Histology Attention

Sep 2026 · 0 citations · 16 references
Computer Science

TL;DR

Across four external evaluations in colon, renal, lung, and glioblastoma cohorts, MIST improves external C-index over standard fusion baselines in the primary comparisons, which support genomic-guided histology attention as a compact and effective strategy for multimodal oncology outcome prediction.

Abstract

Multimodal survival models can combine complementary prognostic information from whole-slide images and genomic profiles, but effective fusion remains challenging amid external cohort shift and computational complexity. To address these challenges, we propose MIST, multimodal survival prediction with genomic-guided histology attention. MIST represents genomic features as tokens and allows them to query compact foundation-model-derived histology context tokens before survival prediction. This design enriches molecular information with histology context rather than merging separately encoded modalities only at the final stage. Training combines discrete-time survival prediction with genomic feature masking, WSI dropout, and paired WSI-genomics contrastive alignment. Across four external evaluations in colon, renal, lung, and glioblastoma cohorts, MIST improves external C-index over standard fusion baselines in the primary comparisons. These results support genomic-guided histology attention as a compact and effective strategy for multimodal oncology outcome prediction. Our code is available at https://github.com/samiyavuuz/MIST .

View source

Similar papers

Review Open access Aug 2026

From data silos to integrated diagnosis: multimodal machine learning in glioblastoma

Recent advances and emerging translational evidence for clinically oriented MML in glioblastoma is summarized, with particular emphasis on MRI-centered systems that integrate imaging with pathology, selected molecular measurements, and longitudinal clinical context.

Amin Zadeh-Shirazi, Bryan W. Day, Hui K. Gan et al. · 0 citations
Preprint Aug 2026

CACSurv: Concordance-Aligned Comparative Learning with Large Language Models for Cancer Survival Prediction

CACSurv reformulates survival modeling as mini-cohort comparative reasoning, where an LLM predicts relative prognostic orderings and introduces concordance-aligned rewards derived from comparable relations under right censoring, enabling censored outcomes to provide ranking supervision without exact event-time targets.

Tianqi Xiang, Qixiang Zhang, Xinpeng Ding et al. · 0 citations
Open access Sep 2026

UMPM-Net: A Multimodal Deep Learning Framework for Colorectal Cancer Prognosis

The proposed UMPM-Net is a comprehensive, explainable and robust multimodal learning framework that is capable of accurate, interpretable, and clinically relevant prognostication for colorectal cancer.

K. Muthuchamy, S. K. Piramu Preethika · 0 citations
Open access Aug 2026

Deep learning-based cross-attention fusion of multimodal MRI for survival prediction and risk stratification in IDH-wildtype glioblastoma: a multicenter study

The CAF-derived risk score offers prognostic information complementary to routine clinical variables, representing a promising noninvasive tool for individualized risk stratification when molecular profiling is incomplete or unavailable; these findings warrant prospective external validation before clinical use.

Shi-Chao Liu, Risheng Liang · 0 citations
Open access Sep 2026

Morphology Predicts Grade, Transcriptomics Predicts Nodal Status: Task-Dependent Modality Contributions in Multimodal Prostate Cancer Classification

Multimodal studies of prostate cancer typically report aggregate fusion gains from histology and transcriptomics but rarely characterize when each modality is informative. We asked whether morphology and transcriptomics contribute differently to distinct clinical endpoints, using Gleason grading and nodal status predic...

Chae-Ki Moon, Ho-Jin Song, Yong Suk Kim · 0 citations
Open access Sep 2026

A multimodal AI biomarker PATH-ORACLE improves prediction of recurrence in stage I lung adenocarcinoma

Background Surgical resection is the standard treatment for stage I lung adenocarcinoma, in most cases without additional systemic adjuvant treatment. A substantial proportion of stage I cases recur, with a 5-year survival rate <50%. Clinical data suggest that adjuvant treatment, including immune checkpoint inhibitor t...

O. Kilim, O. Pipek, Z. Sztupinszki et al. · 0 citations

Related blog posts

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.